Alport syndrome: The effects of spironolactone on proteinuria and urinary TGF-β1

Pediatric Nephrology

Volumn 28, Issue 9, 2013, Pages 1837-1842

  Giani, Marisa ^a   Mastrangelo, Antonio ^a   Villa, Roberta ^a   Turolo, Stefano ^a   Marra, Giuseppina ^a   Tirelli, Amedea Silvia ^a   Hopfer, Helmut ^b   Edefonti, Alberto ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Aldosterone; Alport syndrome; Proteinuria; Renin angiotensin system; Spironolactone; Urinary TGF 1

Indexed keywords

ALDOSTERONE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA1;

ADOLESCENT; ADULT; ALDOSTERONE BLOOD LEVEL; ALLERGIC REACTION; ALPORT SYNDROME; ARTICLE; CHILD; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DRUG EFFICACY; FEMALE; GYNECOMASTIA; HEART ARRHYTHMIA; HUMAN; HYPERKALEMIA; HYPONATREMIA; LIVER DYSFUNCTION; MALE; MUSCLE WEAKNESS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; SCHOOL CHILD; TREATMENT DURATION; URINARY EXCRETION;

EID: 84881071938     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-013-2490-z     Document Type: Article

References (30)

1. Barker DF, Hostikka SL, Zhou J, Chow LT, Oliphant AR, Gerken SC, Gregory MC, Skolnick MH, Atkin CL, Tryggvason K (1990) Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science 248:1224-1227
2. Gubler MC, Knebelmann B, Beziau A, Broyer M, Pirson Y, Haddoum F, Kleppel MM, Antignac C (1995) Autosomal recessive Alport syndrome: Immunohistochemical study of type IV collagen chain distribution. Kidney Int 47:38-44
3. Guney I, Selcuk YN, Altintepe L, Atalay H, Başarali KM, Büyükbaş S (2009) Antifibrotic effects of aldosterone receptor blocker (Spironolactone) in patients with chronic kidney disease. Ren Fail 31:779-784
4. Lai L, Chen J, Hao CM, Lin S, Gu Y (2006) Aldosterone promotes fibronectin production through a Smad2-dependent TGF-β1 pathway in mesangial cells. Biochem Biophys Res Commun 348:70-75
5. 1 in the kidney and urine of patients with glomerular disease and proteinuria. Nephrol Dial Transplant 17:2145-2152
6. Jais JP, Knebelmann B, Giartis I, De Marchi M, Rizzoni G, Renieri A, Weber M, Gross O, Netzer KO, Flinter F, Pirson Y, Dahan K, Wieslander J, Persson U, Tryggvason K, Martin P, Hertz JM, Schröder C, Sanak M, Carvalho MF, Saus J, Antignac C, Smeets H, Gubler MC (2003) X-linked Alport syndrome: Natural history and genotype-phenotype correlations in girls and women belonging to 195 families: A "European Community Alport Syndrome Concerted Action" study. J Am Soc Nephrol 14:2603-2610
7. Gross O, Kashtan CE (2009) Treatment of Alport syndrome: Beyond animal models. Kidney Int 76:599-603
8. Chen D, Jefferson B, Harvey SJ, Gartley CJ, Jacobs RM, Thorner PS (2003) Cyclosporine A slows the progressive renal disease of Alport syndrome (X-linked Hereditary Nephritis): Results from a canine model. J Am Soc Nephrol 14:690-698
9. Massella L, Onetti Muda A, Legato A, Di Zazzo G, Giannakakis K, Emma F (2010) Cyclosporine A treatment in patients with Alport syndrome: A single-center experience. Pediatr Nephrol 25:1269-1275
10. Charbit M, Gubler MC, Dechaux M, Gagnadoux MF, Grünfeld JP, Niaudet P (2007) Cyclosporine therapy in patients with Alport syndrome. Pediatr Nephrol 22:57-63
11. Proesmans W, Van Dyck M (2004) Enalapril in children with Alport syndrome. Pediatr Nephrol 19:271-275
12. Webb NJ, Lam C, Shahinfar S (2011) Efficacy and safety of losartan in children with Alport syndrome - results from a subgroup analysis of prospective, randomized, placebo- or amlodipine-controlled trial. Nephrol Dial Transplant 26:2521-2526
13. Gross O, Licht C, Anders HJ (2012) Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 81:494-501
14. Nakao N, Yoshimura A (2003) Combination treatment of angiotensin II receptor blocker and angiotensin-converting-enzyme inhibitor in non diabetic renal disease. Lancet 361:117-124
15. Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T (2008) Effect of Renin-Angiotensin-Aldosterone system triple blockade on non-diabetic renal disease: Addition of aldosterone blocker, Spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res 31:59-67
16. González Monte E, Andrés A, Polanco N, Toribio ML, Santana R, Gutiérrez Martínez E, González J, Ramírez E, Hernández A, Morales E, Praga M, Morales JM (2010) Addition of spironolactone to dual blockade of renina angiotensin system dramatically reduces severe proteinuria in renal transplant patients: An uncontrolled pilot study at 6 months. Transplant Proc 42:2899-2901
17. Kaito H, Nozu K, Iijima K, Nakanishi K, Yoshiya K, Kanada K, Przybyslaw Krol R, Yoshikawa N, Matsuo M (2006) The effect of aldosterone blockade in patients with Alport syndrome. Pediatr Nephrol 21:1824-1829
18. Kashtan CE, Ding J, Gregory M, Gross O, Heidet L, Knebelmann B, Rheault M, Licht C (2013) Clinical practice recommendations for the treatment of Alport syndrome: A statement of the Alport Syndrome Research Collaborative. Pediatr Nephrol 28:5-11
19. Schwartz GJ, Brion LP, Spitzer A (1987) The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 34:571-590
20. Bianchi S, Bigazzi R, Campese VM (2006) Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 70:2116-2123
21. Park HC, Xu ZG, Choi S, Goo YS, Kang SW, Choi KH, Ha SK, Lee HY, Han DS (2003) Effect of losartan and amlodipine on proteinuria and transforming growth factor-β1 in patients with IgA nephropathy. Nephrol Dial Transplant 18:1115-1121
22. Struthers AD (1995) Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J 16:103-106
23. Nishiyama A, Abe Y (2006) Molecular mechanisms and therapeutic strategies of chronic renal injury: Renoprotective effects of aldosterone blockade. J Pharmacol Sci 100:9-16
24. Tsakas S, Goumenos DS (2006) Accurate measurement and clinical significance of urinary transforming growth factor-beta1. Am J Nephrol 26:186-193
25. Cheon Park H, Gao Xu Z, Choi S, Young SG, Wook Kang S, Hun Choi K, Kyu Ha S, Lee Y, Suk Han D (2003) Effect of losartan and amlodipine on proteinuria and transforming growth factor-β1 in patients with IgA nephropathy. Nephrol Dial Transplant 18:1115-1121
26. 1 in Alport renal disease progression. Kidney Int 56:1662-1673
27. Cosgrove D, Rodgers K, Meehan D, Miller C, Bovard K, Gilroy A, Gardner H, Kotelianski V, Gotwals P, Amatucci A, Kalluri R (2000) Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in Alport glomerular pathogenesis and serve as dual targets for metabolic therapy. Am J Pathol 157:1649-1659
28. Adler L, Mathew R, Futterweit S, Frank R, Gauthier BG, Kashtan CE, Trachtman H (2002) Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: Effect on urinary albumin, TGF-β, and nitrite excretion. BMC Nephrol 3:2-7
29. Bobadilla NA, Gamba G (2007) New insights into the pathophysiology of cyclosporine nephrotoxicity: A role of aldosterone. Am J Physiol Renal Physiol 293:F2-F9
30. Cosgrove D (2012) Glomerular pathology in Alport syndrome: A molecular prospective. Pediatr Nephrol 27:885-890